Financial News

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

FN Media Group Presents USA News Group News Commentary

 

Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer Moonshot” initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Zymeworks Inc. (NASDAQ:ZYME), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), and Amgen Inc. (NASDAQ:AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

 

At the 2023 ASCO Annual Meeting Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) shared exciting results from its important study, called BRACELET-1, with results that caught the eye of RBC Capital. The oral presentation shared at the event described how they’ve been testing a treatment for advanced breast cancer, and it’s looking very promising.

 

The treatment combines Oncolytics’ flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel. Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed. The results of BRACELET-1 showed that this mixture could slow down the cancer significantly. It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

 

For people battling cancer, this means more quality time before the cancer might get worse. Specifically, people getting the combined treatment had about 9.5 good months before the disease advanced, compared to just 6.3 months with only paclitaxel.

 

Moreover, the new treatment was better at shrinking or even eliminating the cancer. An impressive 37.5% of patients responded to the combined treatment, as opposed to just 13.3% with paclitaxel alone.

 

“BRACELET-1’s positive results complement prior phase 2 data showing a statistically significant increase in overall survival when pelareorep was combined with paclitaxel by demonstrating similar robust improvements in PFS and ORR in less heavily pre-treated patients,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “Given this exciting finding, our next step is to discuss our data with the FDA to investigate incorporating dual PFS and OS endpoints into our breast cancer program’s registrational study. Including a PFS endpoint will substantially reduce the time to a pivotal readout from the registrational trial, thereby accelerating pelareorep’s path to potential approval as we work to address the urgent needs of HR+/HER2- breast cancer patients.”

 

Following these encouraging results, Oncolytics Biotech is now ready to take the next steps in advancing its breast cancer program. They’re planning to talk to the FDA and push forward with more registrational studies, having already received Fast Track Designation for pelareorep in the treatment of advanced/metastatic pancreatic cancer, in late 2022. This could make pelareorep an approved treatment for breast cancer sooner than expected.

 

Another highlight from the ASCO presentations was that of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Zymeworks Inc. (NASDAQ:ZYME). Together the two companies presented promising data from a pivotal Phase 2b trial, evaluating the bispecific antibody, zanidatamab, in HER2-amplified biliary tract cancers (BTC), a particularly aggressive group of cancers that currently lack HER2-targeted treatment options.

 

The results were not only presented at ASCO but also concurrently published in The Lancet Oncology. They demonstrated meaningful clinical benefit, including antitumor activity, a confirmed objective response rate (cORR) of 41.3%, a median duration of response (DOR) of 12.9 months, and a median progression-free survival (PFS) of 5.5 months.

 

“The HERIZON-BTC-01 trial advances an exciting field of oncology research where we can leverage next-generation sequencing on BTC patients to understand genomic markers of the disease and choose the appropriate targeted therapies for these patients,” said Shubham Pant, M.D., professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

 

The data clearly outshines current chemotherapy treatments for BTC, which offer only a 5 to 15 percent ORR and median PFS of 1.4 to 4 months. The Zymeworks-Jazz partnership showcased an oral presentation on the pivotal HERIZON-BTC-01 study results demonstrating zanidatamab’s meaningful clinical benefit and tolerable safety profile in patients with HER2-amplified BTC.

 

Zanidatamab has already been granted Breakthrough Therapy designation and two Fast Track designations by the FDA, making it an exciting contender in the fight against these tough-to-treat cancers. These exciting results suggest a potential future where targeted treatments like zanidatamab transform the lives of patients in critical need.

 

With three oral presentations and two poster discussions, and over 25 abstracts, Amgen’s (NASDAQ:AMGN) presence at ASCO included new scientific and clinical research across its diverse oncology portfolio and pipeline, featuring data in hard-to-treat tumor types like non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and small cell lung cancer (SCLC).

 

“Our presentations at ASCO… illustrate how we’re advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “We’re focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer.”

 

Highlights from Amgen’s presentations included data on LUMAKRAS® (sotorasib) from the first study evaluating its intracranial efficacy as a KRAS G12C inhibitor versus docetaxel in treated KRAS G12C-mutated advanced NSCLC. Additional analyses from DeLLphi-300 highlighted the safety and clinical efficacy of Tarlatamab, an investigational first-in-class BiTE® immunotherapy, in patients with SCLC with treated and stable brain metastases. Other studies presented novel combinations showing encouraging safety and efficacy in pre-treated KRAS G12C-mutated metastatic CRC and first-line NSCLC.

 

These presentations showed advances in several therapeutic areas, including hematologic malignancies, melanoma/skin cancers, and gastrointestinal cancers. Some of the key clinical studies presented include the IKEMA study for KYPROLIS®, the PARADIGM trial for VECTIBIX®, and a phase 2 study on IMLYGIC® in advanced sarcoma.

 

One company also potentially (yet indirectly) making significant strides in the oncology sector is Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a Newark, California-based biopharmaceutical firm. Although not traditionally labeled as a cancer biotech firm, their innovative approach towards blood disorders, notably Polycythemia Vera, a slow-growing blood cancer, underscores their contribution to the broader oncology landscape.

 

Protagonist’s leading drug candidate, rusfertide (PTG-300), is currently under the microscope. The company recently announced that additional data from the REVIVE study of rusfertide in polycythemia vera would be presented at the annual Congress of the European Hematology Association (EHA). This study holds immense promise as it explores the ability of rusfertide to improve symptoms related to this blood disorder.

 

The Moffitt Cancer Center and the Department of Malignant Hematology have taken a keen interest in this study, suggesting rusfertide’s potential broader application in the field of hematology and possibly in other forms of cancer. An assistant member of the Department, Dr. Andrew Kuykendall, will present the study results, further demonstrating the deep links between Protagonist’s work and oncology professionals.

 

Moreover, Protagonist is also advancing their peptide-based new chemical entity, JNJ-2113 (formerly PN-235), which recently showed positive topline results in treating moderate-to-severe plaque psoriasis. While psoriasis is not a form of cancer, the advancement of these biological drugs signals a new direction in treating various human conditions, including cancers.

 

Article Source: https://usanewsgroup.com/2023/05/31/could-this-company-be-on-track-to-cure-pancreatic-and-breast-cancer-2/  

 

Article Source: 

USA News Group
http://USAnewsgroup.com
info@usanewsgroup.com

  

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

 

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

 

USA News Group is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein.  The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.

 

This release contains “forward-loking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

 

Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611

 

SOURCE USA News Group

The post Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty appeared first on Financial News Media.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback